C-reactive protein in urologic cancers

Huang, Jonathan; Baum, Yoram; Alemozaffar, Mehrdad; Ogan, Kenneth; Harris, Wayne; Küçük, Ömer; Master, Viraj A.

doi:10.1016/j.mam.2015.04.001

Cited by 28 publications

(32 citation statements)

References 86 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…18 A large body of studies has shown that a high CRP was negatively correlated with the prognosis of mPCa patients, but it was not a prognostic predictor in localized PCa. 18 With respect to ANC, a higher ANC was not associated with biochemical recurrence-free survival but with poor OS in localized PCa. 27 Taken together, there have been numerous studies on the relationships between inflammatory markers and the prognosis of patients with PCa, but the roles of these parameters in PCa have not yet been established.…”

Section: Discussionmentioning

confidence: 99%

“…In addition, a past report showed that an increased CRP level is related to PCa risk 26 . CRP is an acute phase reactant indicating the presence of systemic infection, trauma, and malignancy 18 . A large body of studies has shown that a high CRP was negatively correlated with the prognosis of mPCa patients, but it was not a prognostic predictor in localized PCa 18 .…”

Section: Discussionmentioning

confidence: 99%

“…CRP is an acute phase reactant indicating the presence of systemic infection, trauma, and malignancy 18 . A large body of studies has shown that a high CRP was negatively correlated with the prognosis of mPCa patients, but it was not a prognostic predictor in localized PCa 18 . With respect to ANC, a higher ANC was not associated with biochemical recurrence‐free survival but with poor OS in localized PCa 27 .…”

Section: Discussionmentioning

confidence: 99%

“…To date, growing evidence has shown that the local immune responses and systemic inflammation play a role in cancer progression and affect the survival of patients with cancer 14 . The peripheral inflammation markers such as the neutrophil‐lymphocyte ratio (NLR), platelet‐lymphocyte ratio (PLR), lactate dehydrogenase (LDH), and C‐reactive protein (CRP) have been studied for their prognostic values in various types of cancers 15‐18 . Several studies showed that these simple, noninvasive, and readily available markers can predict treatment response and survival outcomes also in patients with PCa 10,11 .…”

Section: Introductionmentioning

confidence: 99%

“…14 The peripheral inflammation markers such as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), lactate dehydrogenase (LDH), and C-reactive protein (CRP) have been studied for their prognostic values in various types of cancers. [15][16][17][18] Several studies showed that these simple, noninvasive, and readily available markers can predict treatment response and survival outcomes also in patients with PCa. 10,11 On the other hand, which inflammation markers are superior and the increased usefulness of combining them has not been well studied.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Prognostic value of an inflammatory index for patients with metastatic castration‐resistant prostate cancer

et al. 2020

View full text Add to dashboard Cite

Background The inflammatory process has been reported to be involved in the formation and progression of various types of cancer. Recently, a peripheral inflammatory index, combining the derived neutrophils/(leukocytes minus neutrophils) ratio (dNLR) and the lactate dehydrogenase (LDH) level, was proposed as a useful prognostic marker in advanced nonsmall cell lung cancer. The prognostic value of inflammatory markers in prostate cancer has not been established. We aimed to validate the prognostic significance of this peripheral inflammatory index in metastatic castration‐resistant prostate cancer (mCRPC). Methods Clinical data of 196 mCRPC patients were retrospectively collected from multiple institutions. Clinical factors and inflammatory markers at the development of CRPC, including white blood cell count, absolute neutrophil count, dNLR, neutrophil‐lymphocyte ratio, platelet‐lymphocyte ratio, C‐reactive protein (CRP), and LDH levels, were evaluated. The patients were classified into three groups based on the inflammatory index: Good (low dNLR and LDH), Intermediate (high dNLR or LDH), and Poor (high dNLR and LDH). Overall survival (OS) and cancer‐specific survival after CRPC were analyzed using Cox proportional hazard models and Kaplan‐Meier methods. Results The median age and baseline prostate‐specific antigen level were 75 years and 397.15 ng/mL, respectively. On multivariate analysis, dNLR (≥1.51; hazard ratio [HR] = 1.624; P = .0173), LDH (≥upper limit of normal; HR = 2.065; P = .0004), alkaline phosphatase (≥310 U/L; HR = 2.546; P < .0001), and positive N stage (HR = 1.621; P = .048) were associated with poor OS after CRPC, whereas other inflammatory markers including the NLR were not. The Good inflammatory index group showed significantly longer OS after CRPC compared to the Intermediate and Poor groups, with median survivals of 46.2, 28.9, and 16.6 months, respectively. Conclusions The novel inflammatory index combining dNLR and LDH was a useful prognostic parameter in patients with mCRPC. Our analysis suggested that dNLR emerged as a more valuable prognostic marker than NLR.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%